Abstract
The coronavirus disease 2019 (COVID-19) outbreak started in late 2019 in Wuhan, Hubei Province of China, and quickly spread to the surrounding regions and neighboring countries. A novel coronavirus, the so-called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found to be responsible for this outbreak potentially originating from pangolins. In China, the outbreak lasted for 1 month until it seemed to be controlled after affecting over 81,000 individuals and causing deaths in over 4200 patients. Subsequently, and after affecting over 118,000 individuals and causing over 4200 deaths, the condition was officially announced as a pandemic by the World Health Organization (WHO). In the meantime, the epidemic curve took a downtrend in China, the original epicenter of the pandemic, but started to rise in other countries with a steep slope. Among over 215 affected countries, the USA, European countries (Italy, Germany, Spain, France, the UK), Iran, and South Korea had the highest frequencies in the matters of infected patients and deaths. Importantly, different countries took different policies when encountered with an outbreak, especially in the matter of accuracy of the report and timing of the action. A part of the delays in reporting was expected, including the lag in the chain of reporting, the shortcomings of tests, missed patients, and inadequate testing facilities. However, there were also political and nontechnical reasons that caused the reporting to be inaccurate. Surveillance seems to be less of a reason for the observed in poor management, and it mostly originated from human decision-making failures and political issues. Besides, the culture of populations and their trust in their governments played an important role on how they reacted to the COVID-19 pandemic and acquired policies. Finally, the characteristics of the world today indicate the danger of probable upcoming outbreaks, and policymakers should utilize the existing opportunities, particularly the advancements in technology and media, to prevent or adequately manage them.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahanchian H, Moazzen N, Faroughi MSD, Khalighi N, Khoshkhui M, Aelami MH, Haghi NSM, Rezaei N (2020) COVID-19 in a child with primary specific antibody deficiency
Ahmadi M, Saffarzadeh N, Habibi MA, Hajiesmaeili F, Rezaei N (2020) Colon cancer and SARS-CoV-2: impact of ACE2 expression in susceptibility to COVID-19. bioRxiv
Almond D (2006) Is the 1918 influenza pandemic over? Long-term effects of in utero influenza exposure in the post-1940 US population. J Polit Econ 114(4):672–712
Axelrod J (2006) The 5 stages of loss and grief. Psych Central
Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Eur Secur 25(5)
Bahrami A, Vafapour M, Moazzami B, Rezaei N (2020) Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: first case from Iran. J Paediatr Child Health. https://doi.org/10.1111/jpc.15048
Basiri A, Heidari A, Nadi MF, Fallahy MTP, Nezamabadi SS, Sedighi M, Saghazadeh A, Rezaei N (2020a) Microfluidic devices for detection of RNA viruses. Rev Med Virol:e2154. https://doi.org/10.1002/rmv.2154
Basiri A, Pazhouhnia Z, Beheshtizadeh N, Hoseinpour M, Saghazadeh A, Rezaei N (2020b) Regenerative medicine in COVID-19 treatment: real opportunities and range of promises. Stem Cell Rev Rep:1–13
Buhalis D (2020) BRACE the future and time to reignite, refocus, redesign and reengineer our global tourism industry: the new 4Rs of tourism!
CSSEGISandData/COVID-19 (2020). https://github.com/CSSEGISandData/COVID-19/issues
Darbeheshti F, Rezaei N (2020) Genetic predisposition models to COVID-19 infection. Med Hypotheses
de Sousa R, Reusken C, Koopmans M (2014) MERS coronavirus: data gaps for laboratory preparedness. J Clin Virol 59(1):4–11
Fathi N, Rezaei N (2020) Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int
Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, Bhatia S, Boonyasiri A, Cucunuba Perez Z, Cuomo-Dannenburg G (2020) Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand
Fink S (2020) Worst-case estimates for U.S. Coronavirus deaths. The New York Times
Hanaei S, Rezaei N (2020) COVID-19: developing from an outbreak to a pandemic. Arch Med Res. https://doi.org/10.1016/j.arcmed.2020.04.021
Hoffman SJ, Silverberg SL (2018) Delays in global disease outbreak responses: lessons from H1N1, Ebola, and Zika. Am J Public Health 108(3):329–333
Jabbari P, Jabbari F, Ebrahimi S, Rezaei N (2020) COVID-19: a chimera of two pandemics. Disaster Med Public Health Prep:1–2. https://doi.org/10.1017/dmp.2020.223
Jahanshahlu L, Rezaei N (2020) Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother:110337
Kafieh R, Arian R, Saeedizadeh N, Minaee S, Yadav SK, Vaezi A, Rezaei N, Javanmard SH (2020) COVID-19 in Iran: a deeper look into the future. medRxiv
LePan N (2020) A visual history of pandemics. World Economic Forum. https://www.weforum.org/agenda/2020/03/a-visual-history-of-pandemics/. Accessed 31 Mar 2020
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med
Lotfi M, Rezaei N (2020) SARS-CoV-2: a comprehensive review from pathogenicity of the virus to clinical consequences. J Med Virol
Lotfi M, Hamblin MR, Rezaei N (2020) COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta
Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N (2020) The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci 258:118185. https://doi.org/10.1016/j.lfs.2020.118185
Mirbeyk M, Rezaei N (2020) The impact of COVID-19 on pregnancy and neonatal health: a systematic review
Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N (2020) COVID-19 and telemedicine: immediate action required for maintaining healthcare providers well-being. J Clin Virol 126:104345. https://doi.org/10.1016/j.jcv.2020.104345
Mohamed K, Rodríguez-Román E, Rahmani F, Zhang H, Ivanovska M, Makka SA, Joya M, Makuku R, Islam MS, Radwan N (2020a) Borderless collaboration is needed for COVID-19—a disease that knows no borders. Infect Control Hosp Epidemiol:1–2
Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N (2020b) Computational drug discovery and repurposing for the treatment of Covid-19: a systematic review. Available at SSRN 3583748
Momtazmanesh S, Ochs HD, Uddin LQ, Perc M, Routes JM, Vieira DN, Al-Herz W, Baris S, Prando C, Rosivall L (2020) All together to fight COVID-19. Am J Trop Med Hyg 102(6):1181–1183
Moradian N, Ochs HD, Sedikies C, Hamblin MR, Camargo CA, Martinez JA, Biamonte JD, Abdollahi M, Torres PJ, Nieto JJ (2020) The urgent need for integrated science to fight COVID-19 pandemic and beyond. J Transl Med 18(1):1–7
Nasab MG, Saghazadeh A, Rezaei N (2020) SARS-CoV-2–a tough opponent for the immune system. Arch Med Res
Niestadt M (2020) COVID-19 and the tourism sector
Novel CPERE (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi 41(2):145
Organization WH, Organization WH (2020) Report of the who-China joint mission on coronavirus disease 2019 (covid-19)
Pourahmad R, Moazzami B, Rezaei N (2020) Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19. SN Compr Clin Med:1–5
Rabiee N, Rabiee M, Bagherzadeh M, Rezaei N (2020) COVID-19 and picotechnology: potential opportunities. Med Hypotheses 144:109917. https://doi.org/10.1016/j.mehy.2020.109917
Rezaei N (2020) COVID-19 and medical biotechnology. Avicenna J Med Biotechnol 12(3):139–139
Rokni M, Hamblin MR, Rezaei N (2020) Cytokines and COVID-19: friends or foes? Hum Vaccin Immunother:1–3
Rzymski P, Nowicki M, Mullin GE, Abraham A, Rodríguez-Román E, Petzold MB, Bendau A, Sahu KK, Ather A, Naviaux A-F (2020) Quantity does not equal quality: scientific principles cannot be sacrificed. Int Immunopharmacol 86:106711
Saghazadeh A, Rezaei N (2020) Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol 84:106560. https://doi.org/10.1016/j.intimp.2020.106560
Sahu KK, Siddiqui AD, Rezaei N, Cerny J (2020) Challenges for management of immune thrombocytopenia during COVID-19 pandemic. J Med Virol. https://doi.org/10.1002/jmv.26251
Saleki K, Banazadeh M, Saghazadeh A, Rezaei N (2020) The involvement of the central nervous system in patients with COVID-19. Rev Neurosci 1 (ahead-of-print)
Shamshirian D, Rezaei N (2020) Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis
US Department of Health Human Services (2013) Principles of epidemiology in public health practice third edition an introduction to applied epidemiology and biostatistics. Atlanta, Georgia, USA, pp 8. Available on the website: http://www.cdc.gov/ophss/csels/dsepd/SS197
Walker PG, Whittaker C, Watson O, Baguelin M, Ainslie K, Bhatia S, Bhatt S, Boonyasiri A, Boyd O, Cattarino L (2020) The global impact of covid-19 and strategies for mitigation and suppression. WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London
World Health Organization (2019) Middle East respiratory syndrome coronavirus (MERS-CoV), Fact Sheets. https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)
Worst-Case Estimates for U.S. Coronavirus Deaths (2020) The New York Times. https://www.nytimes.com/2020/03/13/us/coronavirus-deaths-estimate.html. Accessed 18 Mar 2020
Yazdanpanah F, Hamblin MR, Rezaei N (2020a) The immune system and COVID-19: friend or foe? Life Sci:117900
Yazdanpanah N, Saghazadeh A, Rezaei N (2020b) Anosmia: a missing link in the neuroimmunology of coronavirus disease 2019 (COVID-19). Rev Neurosci. https://doi.org/10.1515/revneuro-2020-0039
Yousefzadegan S, Rezaei N (2020) Case report: death due to COVID-19 in three brothers. Am J Trop Med Hyg 102(6):1203–1204
Zhang T, Wu Q, Zhang Z (2020) Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hanaei, S. et al. (2021). The Epidemiologic Aspects of COVID-19 Outbreak: Spreading Beyond Expectations. In: Rezaei, N. (eds) Coronavirus Disease - COVID-19. Advances in Experimental Medicine and Biology, vol 1318. Springer, Cham. https://doi.org/10.1007/978-3-030-63761-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-63761-3_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-63760-6
Online ISBN: 978-3-030-63761-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)